Lineage Cell Therapeutics, Inc. LCTX
0.84 USD -0.07 (-8.20%)
As ofNov 16, 2026, 1:44 PM EST
0.8245 Day range 0.95
0.8245 52-week range 1.99
- YTD
- -49.72%
- 1 year
- -55.34%
News
marketbeat.com What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call Lineage Cell Therapeutics NYSEAMERICAN: LCTX has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington's disease cell therapy to its clinical pipeline as the company…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q3 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.13 per share a year ago.benzinga.com Lineage Acquires NeuroAirmid Therapeutics Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s DiseaseAcquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease…
businesswire.com Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q3 2026 Earnings Release.
businesswire.com Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington's Disease CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic,…
